Paradigm Capital analyst Scott McAuley lowered his target a notch on biopharma developer Zymeworks (... Read More
Canadian biotech name Zymeworks (Zymeworks Stock Quote, Chart, News, Analysts, Financials NYSE:ZYME)... Read More
The global pharmaceutical and biotech industry has been getting a lot of attention over the past yea... Read More
Paradigm Capital analyst Scott McAuley still has time for Zymeworks (Zymeworks Stock Quote, Chart, N... Read More
Pharmaceutical companies aren’t every investor’s jam, what with their risk/reward meter at the u... Read More
Paradigm Capital analyst Scott McAuley still has time for Zymeworks (Zymeworks Stock Quote, Chart, N... Read More
The company incurred higher R&D costs over its latest quarter but cancer biopharm company Zymew... Read More
With cash on hand to fund the business through 2022, Zymeworks (Zymeworks Stock Quote, Chart, News N... Read More
Zymeworks (Zymeworks Stock Quote, Chart, News NYSE:ZYME) has what investors should be looking for in... Read More
Paradigm Capital analyst Scott McAuley is expecting big things from clinical stage company Zymeworks... Read More
Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) has... Read More
Paradigm Capital analyst Rahul Sarugaser is expecting 2019 to be a big clinical year for Zymeworks (... Read More
Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) rep... Read More
With a lead drug candidate in a Phase 1 clinical trial and a newly expanded partnership with Japanes... Read More
Vancouver-based biopharm company Zymeworks Inc. (Zymeworks Stock Quote, Chart, News: TSX:ZYME, NYSE:... Read More